Affinergy, a developer of site-specific biological delivery systems for drugs, has landed a deal with Boston Scientific to explore development of new coatings for cardiovascular stents.

Financial terms were not disclosed.

Affinergy is a spinout from Duke University.

Boston Scientific is a developer and manufacturer of medical devices.

“Boston Scientific has a long history as the innovation and marketshare leader in cardiovascular markets,” said Peyton Anderson, chief executive officer of Affinergy. “Our team is excited to work in a large medical device field where improving clinical outcomes can positively affect patients’ lives. Affinergy looks forward to building this relationship and moving our coatings into development as rapidly as possible.”